HYPERPHOSPHATEMIA

This study tested a drug called MCI-196 in 245 adults on dialysis who have high phosphate levels, a common problem in advanced kidney disease. After a 4-week washout and 12-week dose adjustment, patients were randomly assigned to continue MCI-196 or switch to a placebo for 4 week…

This study tested the long-term safety of a drug called MCI-196 (Colestilan) in 116 adults with stage 5 chronic kidney disease who are on dialysis and have high phosphorus levels. Participants took flexible doses of the drug for 52 weeks. The main goal was to see how many side ef…

This study tested a drug called MCI-196 in 336 adults on dialysis with chronic kidney disease and high phosphorus levels. After a washout period, some patients received MCI-196 and others a placebo to see if the drug could safely lower phosphorus. The goal was to manage a common …

This Phase 3 trial tested MCI-196, a drug that binds phosphorus and lowers cholesterol, in 642 adults on dialysis with chronic kidney disease. Participants received either MCI-196 or a placebo for 12 weeks. The goal was to see if the drug could safely reduce both serum phosphorus…

This study tested the long-term safety of a drug called MCI-196 in 632 adults with chronic kidney disease on dialysis who have high phosphorus levels. Participants took the drug for up to 52 weeks to see how it affected their phosphorus and cholesterol. The goal was to help contr…

This Phase 3 trial tested a new drug called AP301 in 474 Chinese adults on dialysis who had high phosphorus levels. Participants took AP301, a low dose of AP301, or the standard drug sevelamer carbonate with meals. The main goal was to see how well AP301 lowers phosphorus compare…

This completed Phase 1 trial looked at how colestilan, a drug for high phosphate levels in kidney disease, affects the body's processing of candesartan, a blood pressure medication. Eighteen healthy men took candesartan alone or with colestilan at different times. The goal was to…